Gemphire Therapeutics (GEMP)

Gemphire Therapeutics is a clinical-stage biopharmaceutical company headquartered in Michigan focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both. Gemphire licensed its lead asset, gemcabene (CI-1027), from Pfizer in 2011 and is developing it as a novel, once-daily, oral therapy, for patients with high cardiovascular and pancreatitis risk who are unable to achieve normal levels of LDL-C or triglycerides with statins or other therapies. GEMP is focused on a broad spectrum of indications for dyslipidemia patients ranging from the orphan indication of Homozygous Familial Hypercholesterolemia (HoFH) to more prevalent conditions, such as Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD) and Severe Hypertriglyceridemia (SHTG) as well as strategies for leveraging gemcabene’s additive LDL-C lowering characteristics and lack of drug-drug interaction with statins to pursue combination therapies, the foundation of the treatment paradigm for dyslipidemia patients.

Published Reports

GEMP pediatric NAFLD termination rev
GEMP FDA delay rev
GEMP 1Q18 rev
GEMP 4Q17 rev
GEMP NDR 10.17 rev
GEMP update call rev
GEMP 2Q17 rev
GEMP ROYAL-1 rev
GEMP NDR rev
GEMP cobalt data 6.28
GEMP CEO departure rev
GEMP-1Q17-rev.pdf
GEMP 4Q16 rev
GEMP COBALT interim data 1.30.17 rev
GEMP NASH pre-clinical data 1.9.17 rev
GEMP trials update 1 5 17 rev
gemp-management-day-10-18-16-rev2
gemp-initiation-of-coverage-rev-9-5-16-1